Study Evaluating How Patients With Acute Coronary Syndrome Are Managed During 2 Years After Discharge (EPICOR)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01171404
First received: July 27, 2010
Last updated: April 16, 2013
Last verified: April 2013

July 27, 2010
April 16, 2013
September 2010
March 2013   (final data collection date for primary outcome measure)
Clinical outcomes (ischemic and bleeding) incidence and time to these clinical outcomes [ Time Frame: Longitudinal during 2 years after index event (phone calls to the patients at 6 weeks and each 3 months after index event) ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01171404 on ClinicalTrials.gov Archive Site
  • Antithrombotic treatments [ Time Frame: Longitudinal during 2 years after index event (phone calls to the patients at 6 weeks and each 3 months after index event) ] [ Designated as safety issue: No ]
  • Use of health care resources [ Time Frame: Longitudinal during 2 years after index event (phone calls to the patients at 6 weeks and each 3 months after index event) ] [ Designated as safety issue: No ]
  • Quality of life [ Time Frame: At index event (baseline) and then at 6 weeks and each 3 months after index event ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Study Evaluating How Patients With Acute Coronary Syndrome Are Managed During 2 Years After Discharge
Long-term Follow-up of Antithrombotic Management Patterns in Acute Coronary Syndrome Patients

The aim of this international study is to describe the short- and long-term (i.e. up to 2 years following the index event) antithrombotic management patterns (AMPs) in patients hospitalized for acute coronary syndromes (ST segment elevation myocardial infarction (STEMI), Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS)), and to document the impact of AMPs in clinical outcomes, economic variables and quality of life in a 'real-life' setting and to compare these between sites, countries and regions.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

Patients hospitalized within 24 hours of onset of symptoms and diagnosed with unstable angina (UA), STEMI or non-STEMI(NSTEMI). Patients will be invited to participate by the hospital (Academic or Community) which is going to discharge the patient.

Participating investigators will belong to hospitals (Academic, Community, with/without cathlab, etc), in the proportion representing the reality of where this kind of patients are managed in each country.

  • ACS
  • Acute Coronary Syndrome
  • Myocardial Infarction
  • Unstable Angina
  • Coronary Artery Disease
Not Provided
1
Patients, older than 18, hospitalized within 24 hours of onset of symptoms and diagnosed with UA, STEMI or NSTEMI
Bueno H, Danchin N, Tafalla M, Bernaud C, Annemans L, Van de Werf F. EPICOR (long-tErm follow-up of antithrombotic management Patterns In acute CORonary syndrome patients) study: rationale, design, and baseline characteristics. Am Heart J. 2013 Jan;165(1):8-14. doi: 10.1016/j.ahj.2012.10.018. Epub 2012 Nov 20.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
10568
March 2013
March 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of myocardial infarction or unstable angina
  • Hospitalized for the first time within 24 hours of onset of symptoms

Exclusion Criteria:

  • Presence of any condition/circumstance which in the opinion of the investigator could significantly limit the complete follow up of the patient (e.g. tourist, non-native speaker or does not understand the local language, psychiatric disturbances)
  • Current participation in a clinical trial.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Mexico,   Argentina,   Belgium,   Brazil,   Denmark,   Finland,   France,   Germany,   Greece,   Italy,   Luxembourg,   Venezuela,   Netherlands,   Norway,   Poland,   Romania,   Slovenia,   Spain,   Turkey,   United Kingdom
 
NCT01171404
NIS-CEU-DUM-2009/1
No
AstraZeneca
AstraZeneca
Not Provided
Study Director: Mónica Tafalla Medical Department.AstraZeneca Spain
AstraZeneca
April 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP